SCHEMBL23926336

SCHEMBL23926336

CCN(CC)CCc1cccc(C=O)c1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 4/20 0.44
HTR1A P08908 3/20 0.43
TLR2 O60603 1/20 0.42
TLR1 Q15399 1/20 0.42
TLR6 Q9Y2C9 1/20 0.42
GABRA1 P14867 1/20 0.40
GABRB2 P47870 1/20 0.40
IAPP P10997 3/20 0.38
TSHR P16473 1/20 0.38
HTR6 P50406 1/20 0.38
HTR1D P28221 1/20 0.38
HTR2A P28223 1/20 0.37
CDYL Q9Y232 1/20 0.36
DRD3 P35462 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
TRIM24 O15164 1/20 0.35
TRIM33 Q9UPN9 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30118893 1.00 ERN1 (0.44) ERN1HTR1ATLR2TLR1TLR6
SCHEMBL23926346 0.91 ERN1 (0.42) ERN1HTR1ATLR2TLR1TLR6
SCHEMBL30118933 0.91 ERN1 (0.42) ERN1HTR1ATLR2TLR1TLR6
SCHEMBL1527632 0.82 ERN1 (0.52) ERN1TLR2TLR1TLR6GABRA1
SCHEMBL29953931 0.82 ERN1 (0.52) ERN1TLR2TLR1TLR6GABRA1
SCHEMBL21002293 0.81 ERN1 (0.59) ERN1TLR2TLR1TLR6GABRA1
SCHEMBL9915272 0.81 ALOX5 (0.42) ERN1HTR1ATLR2TLR1TLR6
SCHEMBL29607733 0.79 GABRA1 (0.64) ERN1TLR2TLR1TLR6GABRA1
SCHEMBL1527079 0.79 GABRA1 (0.64) ERN1TLR2TLR1TLR6GABRA1
SCHEMBL193427 0.79 ALOX5 (0.49) ERN1TLR2TLR1TLR6GABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4168408-A1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES Alterity Therapeutics Limited (AU) 2023-04-26 EP disclosed
CN-115667256-A Compounds for treating diseases and methods of treating diseases 艾特里提治疗有限公司 2023-01-31 CN disclosed
WO-2021253091-A1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES Alterity Therapeutics Limited (AU) 2021-12-23 WO disclosed
US-11155547-B1 Compounds for and methods of treating diseases Alterity Therapeutics Limited (AU) 2021-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11155547-B1 Compounds for and methods of treating diseases HTT, SNCA, PARK7 ERN1 3580/4885HTR1A 668/4885TLR2 4740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.